Updated:
Lundbeck Foundation
The Lundbeck Foundation was established in 1954 by Grete Lundbeck, widow of H. Lundbeck A/S founder Hans Lundbeck, with the dual mandate of stewarding the...
Lundbeck Foundation
The Lundbeck Foundation was established in 1954 by Grete Lundbeck, widow of H. Lundbeck A/S founder Hans Lundbeck, with the dual mandate of stewarding the pharmaceutical company's equity and funding brain research. Today the foundation remains anchored in Copenhagen, operating as one of Denmark's largest commercial foundations, with Lene Skole as CEO and former A.P. Moller-Maersk chief Søren Skou as board chair. The foundation deploys capital across a mix of public equities, direct venture and growth-stage biotech investments, and real property. Its biotech portfolio includes a co-investment alongside Novo Holdings in Ellab, a supplier of validation and monitoring equipment to the life sciences sector, and a joint stake with EQT in WS Audiology, the hearing aid manufacturer formed through the 2019 merger of Sivantos and Widex. The foundation also holds a directly owned real estate portfolio spanning commercial, residential, and mixed-use properties in Copenhagen and Aalborg — including the KEA Empire Campus and the CobraHave residential block — plus a Scottish timberland portfolio operating as Scottish Woodlands. The foundation distributes more than DKK 500 million in grants each year, predominantly to brain science and healthcare research in Denmark. On the real estate side, it maintains a joint venture with Danish investment firm C.W. Obel through Obel-LFI Ejendomme A/S, which manages several properties in Copenhagen and Aalborg. In May 2024, the foundation confirmed its ongoing commitment to commercializing foundational biotechnology research out of Danish universities, reinforcing its role as a bridge between academic labs and the private market. The foundation's structure as an enterprise foundation — holding majority voting control of a publicly listed company while maintaining an independent investment arm — gives it a dual identity not typically found in single-family offices. Governance is layered: the board oversees both the foundation's grant-making and its stewardship of the Lundbeck A/S stake, while CEO Lene Skole leads an in-house team managing direct investments alongside external fund commitments. This architecture allows grant distributions to run in parallel with an active principal investment strategy, rather than one being a derivative of the other.
General information
Firm type
Endowment / Foundation
Year founded
1954
AUM
Undisclosed
Location
Region
Europe
Country
Denmark
City
Copenhagen
Corporate office
Copenhagen, Denmark
Principals
Lene Skole
CEO
Søren Skou
Chair of the Board
Sector focus
Frequently asked questions
What is the relationship between the Lundbeck Foundation and H. Lundbeck A/S?
The foundation is the controlling shareholder of H. Lundbeck A/S, the Copenhagen-listed pharmaceutical company founded by Hans Lundbeck in 1915. Through its enterprise foundation structure, the Lundbeck Foundation holds a majority of voting shares, which funds its grant-making and investment activities. The foundation operates independently from the company's day-to-day management.
How does the foundation balance its grant-making with its principal investment activity?
Grant distributions, which exceed DKK 500 million annually, are funded by dividends from the Lundbeck A/S stake and returns from the foundation's direct investment portfolio. The investment team manages a separate pool of capital across biotech opportunities, real estate assets, and co-investments alongside institutional partners like EQT and Novo Holdings. This structure allows the grant program to operate with a stable, non-correlated funding base.
What is the foundation's investment posture in biotech?
The foundation invests directly in growth-stage and venture-stage biotech companies, often alongside co-investors such as Novo Holdings and EQT. Confirmed positions include WS Audiology and Ellab. It also supports commercialization of university research in Denmark, effectively acting as a bridge between academic labs and later-stage institutional capital.
Does the Lundbeck Foundation participate in real estate directly or through external funds?
The foundation owns property directly and through its joint venture with C.W. Obel, Obel-LFI Ejendomme A/S. Its holdings include commercial and residential assets in Copenhagen and Aalborg, such as the KEA Empire Campus and Amaliegade 10. The portfolio also extends to timberland in Scotland through Scottish Woodlands.
Who chairs the board of the Lundbeck Foundation?
Søren Skou, the former CEO of A.P. Moller-Maersk, chairs the board. Under his stewardship, the board provides governance oversight for both the foundation's grant-making arm and its stewardship of the H. Lundbeck A/S stake.
Does the foundation accept external capital or operate multi-family-office services?
No. The Lundbeck Foundation manages its own endowment exclusively and does not open its platform to outside families. It operates as a single enterprise foundation with a public mission; its investment activity serves only to fund its grant programs.
What sectors or geographies does the foundation actively avoid?
The foundation concentrates heavily on domestic Danish brain research for its grant-making. Its investments, while spanning Europe, are centered on life sciences and real estate in Denmark and Scotland. It has disclosed no activity in non-European markets or sectors outside its core areas of pharmaceuticals, biotech, timberland, and property.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on endowments & foundations?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: